G4S plc
16.2.2021 12:40:15 CET | Globenewswire | Press release
16 February 2021
G4S PLC
NOTIFICATION OF MAJOR SHAREHOLDING
The company was notified on 15 February 2021 by Societe Generale SA, that following a disposal of voting rights attached to shares they now hold less than 5% of the company's total voting rights
Celine Barroche
Company Secretary
For further enquiries, please contact:
| Helen Parris | Director of Investor Relations | +44 (0) 207 9633189 |
| Media enquiries | ||
| Sophie McMillan | Head of media | +44 (0) 759 5523483 |
| Press office | +44 (0) 207 9633333 |
Notes to Editors:
G4S is the world’s leading global, integrated security company, specialising in the provision of security services and solutions to customers. Our mission is to create material, sustainable value for our customers and shareholders by being the supply partner of choice in all our markets.
G4S is quoted on the London Stock Exchange and has a secondary stock exchange listing in Copenhagen. After taking account of the businesses being sold in the year, G4S is active in around 85 countries and has around 533,000 employees. For more information on G4S, visit www.g4s.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV23.3.2026 07:30:00 CET | Press release
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
Sampo plc23.3.2026 07:30:00 CET | Press release
Sampo has received approval for its extended Group Partial Internal Model
Basilea Pharmaceutica International Ltd, Allschwil23.3.2026 07:15:00 CET | Press release
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Novartis Pharma AG23.3.2026 07:15:00 CET | Press release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
CoaguSense, Inc.23.3.2026 07:00:00 CET | Press release
CoaguSense Announces Agreement to Acquire DOASENSE DOAC Testing Business, Expanding Leadership in Anticoagulation Monitoring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
